DOPACEF 200MG-5ML Dopamine Injection

Product Description

Dopacef - Dopacef Hydrochloride Injection, Usp Is A Clear, Practically Colorless, Aqueous, Additive Solution For Intravenous Infusion After Dilution. Each Ml Contains Either 40 Mg, 80 Mg, Or 160 Mg Dopacef Hcl, Usp (equivalent To 32.3 Mg, 64.6 Mg And 129.2 Mg Dopacef Base Respectively) In Water For Injection, Usp, Containing 9 Mg Sodium Metabisulfite As An Antioxidant. The Ph Range (2.5 To 5.0) May Be Adjusted With Citric Acid And/or Sodium Citrate. The Solution Is Sterile And Nonpyrogenic. Dopacef Hcl, A Naturally Occurring Catecholamine, Is An Inotropic Vasopressor Agent. Its Chemical Name Is 3,4 Dihydroxyphenethylamine Hydrochloride And Its Chemical Structure Is.

Dopacef Is Indicated For The Correction Of Hemodynamic Imbalances Present In The Shock Syndrome Due To Myocardial Infarctions, Trauma, Endotoxic Septicemia, Open Heart Surgery, Renal Failure, And Chronic Cardiac Decompensation As In Congestive Failure. Where Appropriate, Restoration Of Blood Volume With A Suitable Plasma Expander Or Whole Blood Should Be Instituted Or Completed Prior To Administration Of Dopacef. Patients Most Likely To Respond Adequately To Dopacef Are Those In Whom Physiological Parameters, Such As Urine Flow, Myocardial Function, And Blood Pressure, Have Not Undergone Profound Deterioration. Multiclinic Trials Indicate That The Shorter The Time Interval Between Onset Of Signs And Symptoms And Initiation Of Therapy With Volume Correction And Dopacef, The Better The Prognosis.

Urine Flow Appears To Be One Of The Better Diagnostic Signs By Which Adequacy Of Vital Organ Perfusion Can Be Monitored. Nevertheless, The Physician Should Also Observe The Patient For Signs Of Reversal Of Confusion Of Comatose Condition. Loss Of Pallor, Increase In Toe Temperature, And/or Adequacy Of Nail Bed Capillary Filling May Also Be Used As Indices Of Adequate Dosage.
Clinical Studies Have Shown That When Dopacef Is Administered Before Urine Flow Has Diminished To Levels Approximating 0.3 Ml/minute, Prognosis Is More Favorable. Nevertheless, In A Number Of Oliguric Or Anuric Patients, Administration Of Dopacef Has Resulted In An Increase In Urine Flow Which In Some Cases Reached Normal Levels. Dopacef May Also Increase Urine Flow In Patients Whose Output Is Within Normal Limits And Thus May Be Of Value In Reducing The Degree Of Preexisting Fluid Accumulation. It Should Be Noted That At Doses Above Those Optimal For The Individual Patient Urine Flow May Decrease, Necessitating Reduction Of Dosage. Concurrent Administration Of Dopacef And Diuretic Agents May Produce An Additive Or Potentiating Effect. Increased Cardiac Output Is Related To The Direct Inotropic Effect Of Dopacef On The Myocardium.